NCT00134134

Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (planned)
• Sponsor: NYU Langone Health · Academic / Other
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.

Detailed description

The primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa. The secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease, as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.

Conditions

• Hidradenitis Suppurativa

Interventions

Type	Name	Description
DRUG	efalizumab

Timeline

• Start date: 2005-02-01
• Completion: 2006-08-01
• First posted: 2005-08-24
• Last updated: 2006-09-11

Locations

1 site across 1 country: United States